Expanding the family of extracellular chaperones: Identification of human plasma proteins with chaperone activity
- 23 September 2021
- journal article
- research article
- Published by Wiley in Protein Science
- Vol. 30 (11) , 2272-2286
Abstract
Proteostasis, the balance of protein synthesis, folding and degradation, is essential to maintain cellular function and viability, and the many known intracellular chaperones are recognized as playing key roles in sustaining life. In contrast, the identity of constitutively secreted extracellular chaperones (ECs) and their physiological roles in extracellular proteostasis is less completely understood. We designed and implemented a novel strategy, based on the well‐known propensity of chaperones to bind to regions of hydrophobicity exposed on misfolding proteins, to discover new ECs present in human blood. We used a destabilized protein that misfolds at 37°C as “bait” to bind to potential ECs in human serum and captured the complexes formed on magnetic beads. Proteins eluted from the beads were identified by mass spectrometry and a group of seven abundant serum proteins was selected for in vitro analysis of chaperone activity. Five of these proteins were shown to specifically inhibit protein aggregation. Vitronectin and plasminogen activator‐3 inhibited both the in vitro aggregation of the Alzheimer's β peptide (Aβ1–42) to form fibrillar amyloid, and the aggregation of citrate synthase (CS) to form unstructured (amorphous) aggregates. In contrast, prothrombin, C1r, and C1s inhibited the aggregation of Aβ1–42 but did not inhibit CS aggregation. This study thus identified five novel and abundant putative ECs which may play important roles in the maintenance of extracellular proteostasis, and which apparently have differing abilities to inhibit the amorphous and amyloid‐forming protein aggregation pathways.Keywords
This publication has 54 references indexed in Scilit:
- Molecular Chaperone Functions in Protein Folding and ProteostasisAnnual Review of Biochemistry, 2013
- Interaction of Clusterin and Matrix Metalloproteinase-9 and Its Implication for Epithelial Homeostasis and InflammationThe American Journal of Pathology, 2012
- Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer riskMolecular Neurodegeneration, 2012
- The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β1−40 peptideNature Structural & Molecular Biology, 2011
- Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptakeCell Stress and Chaperones, 2010
- Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's diseaseNature Genetics, 2009
- Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous SystemJournal of Cerebral Blood Flow & Metabolism, 2007
- Clusterin, an Abundant Serum Factor, Is a Possible Negative Regulator of MT6-MMP/MMP-25 Produced by NeutrophilsJournal of Biological Chemistry, 2003
- Interaction of Apolipoprotein J-Amyloid β-Peptide Complex with Low Density Lipoprotein Receptor-related Protein-2/MegalinJournal of Biological Chemistry, 1997
- Clusterin binds by a multivalent mechanism to the Fc and Fab regions of IgGBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1992